The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy

International Journal of Rheumatic Diseases

Volumn 12, Issue 3, 2009, Pages 192-206

  Strange, Geoff ^a   Nash, Peter ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Digital ulcers; Pulmonary arterial hypertension; Raynaud's phenomenon; Scleroderma renal crisis; Systemic sclerosis

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICOAGULANT AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; FLUOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; LOSARTAN; NICARDIPINE; NIFEDIPINE; NITRATE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTANOID; QUINAPRIL; SILDENAFIL; SIMVASTATIN; TADALAFIL; UNINDEXED DRUG;

ADJUVANT THERAPY; ANALGESIA; ANTIBIOTIC THERAPY; BANDAGES AND DRESSINGS; CLINICAL TRIAL; DIGITAL ULCER; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HEADACHE; HUMAN; HYPOTENSION; KIDNEY DISEASE; KIDNEY FAILURE; LOW DRUG DOSE; MEDICAL DECISION MAKING; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVASCULARIZATION; REVIEW; SCLERODERMA; SYMPATHECTOMY; SYMPTOMATOLOGY; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; ULCER; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; SCLERODERMA, SYSTEMIC; VASCULAR DISEASES;

EID: 69149085602     PISSN: 17561841     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2009.01410.x     Document Type: Review

References (70)

1. Korn JH, Mayes M, Matucci-Cerinic M, et al. (2004) Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50, 3985-93.
2. Guiducci S, Cerinic MM (2008) Lack of efficacy of quinapril on vascular damage in limited cutaneous systemic sclerosis. Nat Clin Pract Rheumatol 4, 288-9.
3. Coghlan JG, Mukerjee D (2001) The heart and pulmonary vasculature in scleroderma: Clinical features and pathobiology. Curr Opin Rheumatol 13, 495-9.
4. Hummers LK, Wigley FM (2003) Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am 29, 293-313.
5. Campbell PM, LeRoy EC (1975) Pathogenesis of systemic sclerosis: A vascular hypothesis. Semin Arthritis Rheum 4, 351-68.
6. LeRoy EC (1996) Systemic sclerosis: A vascular perspective. Rheum Dis Clin North Am 22, 675-94.
7. Ferri C, Valentini G, Cozzi F, et al. (2002) Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc): Systemic sclerosis: Demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 81, 139-53.
8. Ingraham KM, Steen VD (2006) Morbidity of digital tip ulcerations in scleroderma [abstract]. Arthritis Rheum 54(Suppl. 9), 578.
9. Steen VD, Medsger TA Jr (2007) Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66, 940-4.
10. Denton CP, Lapadula G, Mouthon L, Müller-Ladner U (2009) Renal complications and scleroderma renal crisis. Rheumatology 48(Suppl. 3), iii32-5.
11. Kobayashi H, Nishimaki T, Kaise S, et al. (1999) Immunohistological study endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis. Clin Rheumatol 18, 425-7.
12. Lee S, Lee S, Sharma K (2004) The pathogenesis of fibrosis and renal disease in scleroderma: Recent insights from glomerulosclerosis. Curr Rheumatol Rep 6, 141-8.
13. Coghlan JG, Handler C (2006) Connective tissue associated pulmonary arterial hypertension. Lupus 15, 138-42.
14. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV (2007) Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. Chest 131, 1917-28.
15. Hachulla E, de Groote P, Gressin V, et al. (2009) The 3-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study (ItinérAIR-Sclérodermie Study). Arthritis Rheum 60, 1831-9.
16. Hachulla E, de Groote P, Gressin V, et al. (2009) Risk factors for death and the 3-year survival of patients with systemic sclerosis: The French ItinérAIR-Sclérodermie study. Rheumatology 48, 304-8.
17. Galiè N, Rubin LJ, Hoeper M, et al. (2008) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): A double-blind, randomised controlled trial. Lancet 371, 2093-100.
18. Humbert M, Morrell NW, Archer SL, et al. (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43(12 Suppl. S), 13S-24S.
19. Thompson AE, Pope JE (2005) Calcium channel blockers for primary Raynaud's phenomenon: A meta-analysis. Rheumatology (Oxford) 44, 145-50.
20. Wigley FM, Korn JH, Csuka ME, et al. (1998) Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study. Arthritis Rheum 41, 670-7.
21. Black CM, Halkier-Sørensen L, Belch JJ, et al. (1998) Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: A multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol 37, 952-60.
22. Pope J, Fenlon D, Thompson A, et al. (2000) Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2, CD000953.
23. Kawald A, Burmester GR, Huscher D, Sunderkötter C, Riemekasten G (2008) Low versus high-dose iloprost therapy over 21days in patients with secondary Raynaud's phenomenon and systemic sclerosis: A randomized, open, single-center study. J Rheumatol 35, 1830-7.
24. Lichtenstein JR (2003) Use of sildenafil citrate in Raynaud's phenomenon: Comment on the article by Thompson et al. Arthritis Rheum 48, 282-3.
25. Gore J, Silver R (2005) Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 64, 1387.
26. Shenoy P, Agarwal V, Kumar S, et al. (2008) Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: A double blind randomized cross over trial [abstract]. ACR abstract 639.
27. Carlino G (2005) Treatment of Raynaud's phenomenon with tadalafil, a phosphodiesterase-5 inhibitor [abstract]. Ann Rheum Dis 64(Suppl. III), 258.
28. Kuwana M, Kaburaki J, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y (2006) Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum 54, 1946-51.
29. Abou-Raya A, Abou-Raya S, Helmii M (2008) Statins: Potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol 35, 1801-8.
30. Coleiro B, Marshall SE, Denton CP, et al. (2001) Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 40, 1038-43.
31. Dziadzio M, Denton CP, Smith R, et al. (1999) Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42, 2646-55.
32. Gliddon AE, Doré CJ, Black CM, et al. (2007) Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 56, 3837-46.
33. Kowal-Bielecka O, Landewé R, Avouac J, et al. (2009) EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68, 620-8.
34. Sorrentino S, Landmesser U (2005) Non-lipid lowering effects of statins. Curr Treat Options Cardiovasc Med 7, 459-66.
35. Llevadot J, Murasawa S, Kureishi Y, et al. (2001) HMG CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 108, 365-6.
36. Sherber NS, Wigley FM, Scher RK (2007) Autoimmune disorders: Nail signs and therapeutic approaches. Dermatol Ther 20, 17-30.
37. Chung L, Fiorentino D (2006) Digital ulcers in patients with systemic sclerosis. Autoimmun Rev 5, 125-8.
38. Vancheeswaran R, Magoulas T, Efrat G, et al. (1994) Circulating endothelin-1 levels in systemic sclerosis subsets-a marker of fibrosis or vascular dysfunction? J Rheumatol 21, 1838-44.
39. Rademaker M, Cooke ED, Almond NE, et al. (1989) Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: A double blind randomised study. BMJ 298, 561-4.
40. Badesch DB, Tapson VF, McGoon MD, et al. (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132, 425-34.
41. Wigley FM, Wise RA, Seibold JR, et al. (1994) Intravenous iloprost in patients with Raynaud's phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120, 199-206.
42. Seibold J, Denton CP, Furst DE, et al. (2005) Bosentan prevents occurrence but does not speed healing of digital ulcers in patients with systemic sclerosis (SSc) [abstract]. Arthritis Rheum 52(Suppl. 9), 552.
43. Sandorfi N, Jimenez SA (2007) Treatment of digital ulceration due to Raynaud's phenomenon with long acting phosphodiesterase 5 (PDE5) inhibitor: Tadalafil [abstract]. Ann Rheum Dis 66(Suppl. II), 223.
44. DISTOL-1 trial. Digital ischemic lesions in scleroderma treated with oral treprostinil diethanolamine (DISTOL-1). Accessed November 10, 2008, http://clinicaltrials.gov/ct2/show/NCT00775463.
45. Shi-Wen X, Denton CP, Dashwood MR, et al. (2001) Fibroblast matrix gene expression and connective tissue remodeling: Role of endothelin-1. J Invest Dermatol 116, 417-25.
46. US National Institutes of Health. A study to evaluate the efficacy of oral medication in the treatment and prevention of digital ulcers in patients with systemic sclerosis (scleroderma). Accessed 10 November 2008, http://clinicaltrials.gov/ct2/show/record/NCT00725361.
47. Steen VD, Medsger TA Jr (2000) Long-term outcomes of scleroderma renal crisis. Ann Intern Med 133, 600-3.
48. Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr (1990) Outcome of renal crisis in systemic sclerosis: Relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 113, 352-7.
49. Steen VD (2003) Scleroderma renal crisis. Rheum Dis Clin North Am 29, 315-34.
50. Walker JG, Ahern MJ, Smith MD, et al. (2003) Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment. Intern Med J 33, 216-20.
51. Penn H, Howie AJ, Kingdon EJ, et al. (2007) Scleroderma renal crisis: patient characteristics and long term outcomes. Q J Med 100, 485-94.
52. Barst RJ, Rubin LJ, Long WA, et al. (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334, 296-302.
53. Olschewski H, Simonneau G, Galiè N, et al. (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347, 322-9.
54. Opitz CF, Wensel R, Winkler J, et al. (2005) Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 26, 1895-902.
55. Hoeper MM, Schwarze M, Ehlerding S, et al. (2000) Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 342, 1866-70.
56. McLaughlin VV, Oudiz RJ, Frost A, et al. (2006) Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174, 1257-63.
57. Simonneau G, Barst RJ, Galie N, et al. (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165, 800-4.
58. Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. (2006) Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: A prospective, multicenter, open-label, 12-week trial. Chest 129, 683-8.
59. Galiè N, Olschewski H, Oudiz RJ, et al. (2008) Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117, 3010-9.
60. Channick RN, Simonneau G, Sitbon O, et al. (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 358, 1119-23.
61. Rubin LJ, Badesch DB, Barst RJ, et al. (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346, 896-903.
62. Denton CP, Pope JE, Peter HH, et al. (2008) TRacleer Use in PAH associated with Scleroderma and Connective Tissue Diseases (TRUST) Investigators. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis 67, 1222-8.
63. Denton CP, Humbert M, Rubin L, Black CM (2006) Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: A subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 65, 1336-40.
64. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM (2007) Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 30, 338-44.
65. Barst RJ, Langleben D, Badesch D, et al. (2006) Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47, 2049-56.
66. Galiè N, Ghofrani HA, Torbicki A, et al. (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353, 2148-57.
67. Badesch DB, Hill NS, Burgess G, et al. (2007) Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 34, 2417-22.
68. Oudiz RJ, Schilz RJ, Barst RJ, et al. (2004) Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 126, 420-7.
69. Gruenig E, Michelakis E, Vachiery J-L, Vizza CD, Meyer J, Galie N (2007) Acute administration of sildenafil in patients with pulmonary arterial hypertension (PAH) treated with bosentan produced a significant hemodynamic response: Results of the COMPASS-1 study [abstract]. Eur Heart J 28(Suppl. 1), 140.
70. Simonneau G, Rubin LJ, Galiè N, et al. (2008) Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Ann Intern Med 149, 521-30.